RPDC concept
Concept for routine practice data collection – nogapendekin alfa inbakicept (urinary bladder carcinoma)
Project details
- Project no.
- A26-68
- Commission
- Commission awarded on 04.06.2026 by the Federal Joint Committee (GBA).
- Report type
- RPDC concept
- Status
- Commission work started
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
Routine practice data collection (RPDC): Review of the study protocol and statistical analysis plan
In the case of new drugs that have entered the health care system via a special marketing authorization or as a drug for the treatment of a rare disease, the study data at the time of marketing authorization are usually not very informative for the early benefit assessment. As in the present case, the GBA can require the pharmaceutical company to collect routine practice data, including the associated analysis, for the benefit assessment. The pharmaceutical company has to submit a study protocol and a statistical analysis plan for the RPDC. IQWiG reviews these documents on behalf of the GBA.
Connected Projects
-
Search for disease registries
Non-muscle invasive urinary bladder carcinoma; assessment according to §35a Social Code Book V; search for disease registries
Status: Commission completed